ANVS
Annovis Bio, Inc.
Related News
SEC Filings
Earnings Trend
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
Annovis Bio NYSE: ANVS said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer's disease trial in March 2027, while preparing a rolling new drug applic
